There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, Section 9.
9. In regulation 20(1)(a), for paragraph (i) substitute—
“(i)which do not have a marketing authorization and are developed by means of one of the following biotechnological processes—
(aa)recombinant DNA technology,
(bb)controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells,
(cc)hybridoma and monoclonal antibody methods, or”.
Commencement Information
I1Reg. 9 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
